Pieris Pharmaceuticals Appoints Ingmar Bruns, M.D., Ph.D., as Vice President of Clinical Development

Pharmaceutical Investing

Pieris Pharmaceuticals (NASDAQ:PIRS) has announced that it has appointed Ingmar Bruns, M.D., Ph..D as vice president of clinical development. As quoted in the press release:  Dr. Bruns is an accomplished physician and brings to Pieris a wealth of oncology and hematology experience, a deep science background, and a strong clinical development acumen. “We are pleased …

Pieris Pharmaceuticals (NASDAQ:PIRS) has announced that it has appointed Ingmar Bruns, M.D., Ph..D as vice president of clinical development.
As quoted in the press release:

 Dr. Bruns is an accomplished physician and brings to Pieris a wealth of oncology and hematology experience, a deep science background, and a strong clinical development acumen.
“We are pleased to welcome Ingmar to the Pieris team at this time of rapid growth and advancement of key therapeutic programs into the clinic,” commented Louis Matis, M.D., Senior Vice President and Chief Development Officer. “His strong biomedical background, academic and industry networks, and track record in both research and clinical development bring exceptional value to the Company. We look forward to his leadership in advancing our lead immuno-oncology therapeutic, PRS-343, a HER2-CD137 first-in-class bispecific, as well as our other programs in immuno-oncology, respiratory and other diseases.”
Prior to joining Pieris, from 2013 through October 2017, Dr. Bruns led clinical development of several high priority oncology assets at Bayer Pharmaceuticals. Before his tenure at Bayer, Dr. Bruns served as an attending hematologist and oncologist as well as a basic, translational and clinical researcher at the University Hospital of Dusseldorf in Germany and Albert Einstein College of Medicine in New York. Dr. Bruns has authored over 50 papers in the field of hematology and oncology. He received his M.D. and Ph.D. from the University of Lubeck in Germany.
“I’m excited to join the dynamic Pieris team and look forward to contributing to the advancement of Pieris’ preclinical and clinical-stage Anticalin-based therapeutics into and through the clinic,” added Dr. Bruns. “In particular, the Company’s lead immuno-oncology program, PRS-343, a HER2-CD137 first-in-class bispecific, represents a potentially transformative therapy for a number of metastatic cancer patients without viable treatment options today.”

Click here to read the full press release.

The Conversation (0)
×